Pulmonary Arterial Hypertension News

Pulmonary Arterial Hypertension	Welcome, Profile Billing Logout

«123 4 5 6 7 8 9 »

|||||||||| Biomarker, Trial completion, Enrollment change: The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD (clinicaltrials.gov) - Nov 22, 2016
P=N/A, N=30, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Completed | N=100 --> 30

||||||||||  treprostinil / Generic mfg.
Trial completion, Trial primary completion date:  ISS: Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin) (clinicaltrials.gov) -  Nov 17, 2016
P4, N=15, Completed,  Sponsor: University of Arizona
Recruiting --> Completed | N=100 --> 30 Trial primary completion date: Dec 2014 --> Dec 2015 | Recruiting --> Completed

||||||||||  Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial primary completion date:  Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years (clinicaltrials.gov) -  Nov 10, 2016
P2, N=40, Recruiting,  Sponsor: United Therapeutics
Trial primary completion date: Dec 2014 --> Dec 2015 | Recruiting --> Completed Trial primary completion date: Oct 2016 --> Jul 2017

||||||||||  carvedilol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date:  Carvedilol PAH A Pilot Study of Efficacy and Safety (clinicaltrials.gov) -  Nov 9, 2016
P2, N=5, Completed,  Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Oct 2016 --> Jul 2017 Recruiting --> Completed | N=25 --> 5 | Trial primary completion date: Dec 2016 --> Jun 2015

|||||||||| Trial primary completion date, Heterogeneity, Compliance: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging (clinicaltrials.gov) - Nov 7, 2016
P=N/A, N=15, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=25 --> 5 | Trial primary completion date: Dec 2016 --> Jun 2015 Trial primary completion date: Jul 2016 --> Jan 2017

||||||||||  treprostinil / Generic mfg.
Enrollment closed:  PKRemodulin: Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) -  Oct 18, 2016
P=N/A, N=51, Active, not recruiting,  Sponsor: Jeffrey A. Feinstein
Trial primary completion date: Jul 2016 --> Jan 2017 Recruiting --> Active, not recruiting

||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion, Trial primary completion date:  Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) -  Oct 12, 2016
P4, N=75, Completed,  Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2016

|||||||||| Trial completion, Enrollment change, Trial primary completion date: PHiano: Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. (clinicaltrials.gov) - Sep 19, 2016
P2, N=31, Completed, Sponsor: Geno LLC
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2016 Recruiting --> Completed | N=54 --> 31 | Trial primary completion date: May 2017 --> Sep 2016

||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date:  Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) -  Sep 9, 2016
P4, N=21, Active, not recruiting,  Sponsor: Los Angeles Biomedical Research Institute
Recruiting --> Completed | N=54 --> 31 | Trial primary completion date: May 2017 --> Sep 2016 Trial primary completion date: Jul 2016 --> Dec 2016

|||||||||| Trial completion: Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Aug 31, 2016
P1/2, N=10, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Completed

||||||||||  carvedilol / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date:  PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol) (clinicaltrials.gov) -  Aug 6, 2016
P=N/A, N=30, Completed,  Sponsor: The Cleveland Clinic
Recruiting --> Completed Recruiting --> Completed | N=68 --> 30 | Trial primary completion date: Jul 2017 --> Jul 2016

|||||||||| Enrollment change, Trial termination, FDG PET: Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. (clinicaltrials.gov) - Jul 30, 2016
P2, N=4, Terminated, Sponsor: Brigham and Women's Hospital
Recruiting --> Completed | N=68 --> 30 | Trial primary completion date: Jul 2017 --> Jul 2016 N=36 --> 4 | Recruiting --> Terminated; Due to lack of funding.

|||||||||| Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=629, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=36 --> 4 | Recruiting --> Terminated; Due to lack of funding. Trial primary completion date: Mar 2016 --> Sep 2016

||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment closed, Compliance:  Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) -  Jul 14, 2016
P=N/A, N=13, Active, not recruiting,  Sponsor: Bayer
Trial primary completion date: Mar 2016 --> Sep 2016 Recruiting --> Active, not recruiting

|||||||||| Enrollment change, Trial primary completion date: PHiano: Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. (clinicaltrials.gov) - Jun 14, 2016
P2, N=54, Recruiting, Sponsor: Geno LLC
Recruiting --> Active, not recruiting N=75 --> 54 | Trial primary completion date: May 2016 --> May 2017

||||||||||  Tracleer (bosentan) / J&J, Roche
Trial primary completion date:  FUTURE 3: Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Jun 10, 2016
P3, N=64, Completed,  Sponsor: Actelion
N=75 --> 54 | Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Aug 2013 --> Apr 2013

||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
Phase classification:  SYMPHONYext: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (clinicaltrials.gov) -  Jun 10, 2016
P3b, N=4, Terminated,  Sponsor: Actelion
Trial primary completion date: Aug 2013 --> Apr 2013 Phase classification: P3 --> P3b

||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
Phase classification:  Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument (clinicaltrials.gov) -  Jun 10, 2016
P3b, N=284, Active, not recruiting,  Sponsor: Actelion
Phase classification: P3 --> P3b Phase classification: P3 --> P3b

|||||||||| Trial completion, Enrollment change: HYPID: Pulmonary Hypertension in Interstitial Lung Disease (clinicaltrials.gov) - Jun 5, 2016
P=N/A, N=224, Completed, Sponsor: Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Phase classification: P3 --> P3b Recruiting --> Completed | N=150 --> 224

||||||||||  Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion, Enrollment change, Trial primary completion date:  A Pharmacokinetic Substudy of the TDE-PH-304 Protocol (clinicaltrials.gov) -  May 26, 2016
P3, N=13, Completed,  Sponsor: United Therapeutics
Recruiting --> Completed | N=150 --> 224 Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Aug 2014 --> Nov 2013

||||||||||  selonsertib (GS-4997) / Gilead
Enrollment change:  ARROW: Selonsertib in Adults With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  May 20, 2016
P2, N=151, Active, not recruiting,  Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=30 --> 13 | Trial primary completion date: Aug 2014 --> Nov 2013 N=120 --> 151

|||||||||| Trial primary completion date: Vascular Subphenotypes of Lung Disease in HIV & COPD (clinicaltrials.gov) - May 12, 2016
P=N/A, N=140, Recruiting, Sponsor: University of Pittsburgh
N=120 --> 151 Trial primary completion date: Jan 2016 --> May 2016

|||||||||| Trial primary completion date: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension (clinicaltrials.gov) - May 10, 2016
P=N/A, N=93, Recruiting, Sponsor: Imperial College London
Trial primary completion date: Jan 2016 --> May 2016 Trial primary completion date: Feb 2016 --> Aug 2016

||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date:  RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) -  May 6, 2016
P3, N=61, Active, not recruiting,  Sponsor: Bayer
Trial primary completion date: Feb 2016 --> Aug 2016 Trial primary completion date: Jun 2016 --> Dec 2017

|||||||||| Trial completion, Enrollment change: Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients (clinicaltrials.gov) - May 4, 2016
P=N/A, N=602, Completed, Sponsor: Georgetown University
Trial primary completion date: Jun 2016 --> Dec 2017 Active, not recruiting --> Completed | N=400 --> 602

||||||||||  Zydena (udenafil) / Mezzion
Trial completion, Trial primary completion date:  Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH (clinicaltrials.gov) -  Apr 18, 2016
P2/3, N=59, Completed,  Sponsor: Dong-A ST Co., Ltd.
Active, not recruiting --> Completed | N=400 --> 602 Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Feb 2016

|||||||||| Biomarker, Trial completion: EFORT: Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=165, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Feb 2016 Active, not recruiting --> Completed

|||||||||| Trial primary completion date: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=55, Recruiting, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Mar 2017

|||||||||| Enrollment change, Trial termination, Trial primary completion date: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder (clinicaltrials.gov) - Mar 21, 2016
P=N/A, N=15, Terminated, Sponsor: University of Utah
Trial primary completion date: Mar 2016 --> Mar 2017 N=60 --> 15 | Withdrawn --> Terminated | Trial primary completion date: Mar 2010 --> Feb 2009; This study was stopped due to poor enrollment numbers

|||||||||| Enrollment change, Trial withdrawal: LONGACT: Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=0, Withdrawn, Sponsor: Actelion
N=60 --> 15 | Withdrawn --> Terminated | Trial primary completion date: Mar 2010 --> Feb 2009; This study was stopped due to poor enrollment numbers N=90 --> 0 | Not yet recruiting --> Withdrawn

||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date:  Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) -  Mar 5, 2016
P4, N=21, Active, not recruiting,  Sponsor: Los Angeles Biomedical Research Institute
N=90 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2015 --> Jul 2016

||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial termination, Trial primary completion date:  SYMPHONYext: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (clinicaltrials.gov) -  Mar 3, 2016
P3, N=4, Terminated,  Sponsor: Actelion
Trial primary completion date: Dec 2015 --> Jul 2016 Active, not recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Protocol-defined criterion of macitentan availability achieved.

|||||||||| Enrollment closed, Trial primary completion date: Adult Congenital Heart Disease Registry (QuERI) (clinicaltrials.gov) - Mar 3, 2016
P=N/A, N=800, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Protocol-defined criterion of macitentan availability achieved. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2018

||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
Trial primary completion date:  GRIPHON: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Mar 1, 2016
P3, N=1156, Completed,  Sponsor: Actelion
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2018 Trial primary completion date: Sep 2014 --> Apr 2014

||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial termination:  A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain (clinicaltrials.gov) -  Feb 29, 2016
P3, N=160, Terminated,  Sponsor: Actelion
Trial primary completion date: Sep 2014 --> Apr 2014 Completed --> Terminated; Slow recruitment

|||||||||| Trial primary completion date: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=93, Recruiting, Sponsor: Imperial College London
Completed --> Terminated; Slow recruitment Trial primary completion date: Nov 2015 --> Feb 2016

||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment closed, Enrollment change:  Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) (clinicaltrials.gov) -  Feb 18, 2016
P4, N=75, Active, not recruiting,  Sponsor: Bayer
Trial primary completion date: Nov 2015 --> Feb 2016 Recruiting --> Active, not recruiting | N=100 --> 75

||||||||||  Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date, Adverse events:  Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) -  Feb 17, 2016
P=N/A, N=1333, Completed,  Sponsor: United Therapeutics
Recruiting --> Active, not recruiting | N=100 --> 75 Trial primary completion date: Jul 2014 --> Dec 2014

||||||||||  emiplacel (PLX-PAD) - Pluristem, Charite / University of Medicine Berlin
PK/PD data, Trial termination, Trial primary completion date:  Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) -  Feb 17, 2016
P1, N=6, Terminated,  Sponsor: United Therapeutics
Trial primary completion date: Jul 2014 --> Dec 2014 Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Dec 2015

|||||||||| Trial completion: EXAP: The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects (clinicaltrials.gov) - Feb 17, 2016
P1, N=12, Completed, Sponsor: Imperial College London
Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Dec 2015 Recruiting --> Completed

|||||||||| Enrollment closed, Trial primary completion date: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Feb 13, 2016
P=N/A, N=800, Active, not recruiting, Sponsor: Actelion
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2018

||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Enrollment open, Trial primary completion date:  PILGRIM: Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Feb 11, 2016
P4, N=48, Recruiting,  Sponsor: Gachon University Gil Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jan 2018 Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jun 2016

||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion, Trial primary completion date:  A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain (clinicaltrials.gov) -  Jan 15, 2016
P3, N=160, Completed,  Sponsor: Actelion
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2014 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Oct 2015

|||||||||| Enrollment closed, Enrollment change, Trial primary completion date: RVMET: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jan 7, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Recruiting --> Completed | Trial primary completion date: Jul 2015 --> Oct 2015 Recruiting --> Active, not recruiting | N=80 --> 20 | Trial primary completion date: Sep 2016 --> Dec 2015

||||||||||  carvedilol / Generic mfg.
Enrollment change, Trial withdrawal:  Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children (clinicaltrials.gov) -  Dec 31, 2015
P1/2, N=0, Withdrawn,  Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting | N=80 --> 20 | Trial primary completion date: Sep 2016 --> Dec 2015 N=10 --> 0 | Suspended --> Withdrawn

|||||||||| Enrollment change, Trial withdrawal: Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 30, 2015
P2, N=0, Withdrawn, Sponsor: American Medical Association Foundation
N=10 --> 0 | Suspended --> Withdrawn N=11 --> 0 | Recruiting --> Withdrawn

|||||||||| Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=629, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=11 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Sep 2015 --> Mar 2016

|||||||||| Trial completion: DYSLIM: Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=199, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Sep 2015 --> Mar 2016 Active, not recruiting --> Completed

||||||||||  epoprostenol intravenous / Generic mfg.
Trial completion:  Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Dec 16, 2015
P3, N=41, Completed,  Sponsor: Actelion
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  anastrozole / Generic mfg.
Trial completion:  Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Dec 6, 2015
P2, N=18, Completed,  Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites